Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

Declining commodity price realizations have hurt YPF's Q1 earnings.

Stantec (STN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Roblox (RBLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Intercorp Financial Services (IFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Examine Steris' (STE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Examine GoPro's (GPRO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Review Cisco's (CSCO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Explore how Applied Materials' (AMAT) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Explore how Brink's' (BCO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cable One, Inc. ("Cable One, Inc.") (NYSE:CABO) concerning possible violations of federal securities laws. On May 2, 2025, Cable One missed earnings expectations by nearly $8 and suspended its dividend.

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cleveland-Cliffs Inc. ("Cleveland-Cliffs Inc.") (NYSE:CLF) concerning possible violations of federal securities laws. Cleveland-Cliffs issued a press release on May 7, 2025, reporting its financial results for the first quarter of 2025.

Last week's economic data presented a mixed bag, arriving against a backdrop of an S&P 500 that trended upwards for the entire week, buoyed by positive developments in trade talks.

Regeneron Pharmaceuticals is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction. The drugmaker is buying 23andMe's Personal Genome Service, Total Health and Research Services business lines, but not its telehealth subsidiary Lemonaid Health.

The cannabis industry is still showing signs of profitability, with companies reporting strong 2025 earnings. Much of the legal market, even with its uphill battle, is standing strong. This shows people that even though it is not federally legal, there is still an abundance of success at the state level. As well as other legal markets in various global regions, all of which play a big role as a whole for cannabis.

The Fund returned 0.98% and the J.P. Morgan CLO AAA Index returned 1.08%. The portfolio's slightly higher spread duration detracted from relative performance, while security selection contributed. We believe the attractive yields in floating-rate collateralized loan obligations are likely to persist amid a persistently strong labor market and a higher-for-longer interest rate environment.

METAIRIE, La.--(BUSINESS WIRE)--Venture Global donated $37,300 to the Coalition to Restore Coastal Louisiana to support critical coastal restoration projects in Louisiana.

BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.